Quarterly instrument placements and total installed base growth (key leading indicator for future reagent revenue)
Reagent pull-through rates per installed instrument (indicates customer utilization and stickiness)
Gross margin trends reflecting product mix shift toward higher-margin consumables
New product launches or technology enhancements expanding addressable applications (e.g., clinical diagnostics approvals)
moderate - Life sciences research spending shows resilience during downturns as NIH funding and pharma R&D budgets are multi-year commitments, but capital equipment purchases can be deferred during budget freezes. Biotech funding cycles (venture capital, IPO markets) significantly impact demand from emerging biopharma customers. Academic and government lab budgets typically lag economic cycles by 12-18 months. Clinical diagnostics demand is more stable but represents smaller portion of current revenue.
Rising rates create headwinds through two channels: (1) biotech funding contraction as venture capital becomes more expensive and risk-averse, reducing instrument demand from emerging companies, and (2) higher discount rates compress valuation multiples for unprofitable growth companies like Cytek. However, the company's minimal debt (0.09 D/E) means direct financing costs are negligible. Customer financing for instrument purchases may become more expensive, potentially extending sales cycles.
Technology obsolescence risk as competitors (BD, Beckman Coulter, Sony Biotechnology) develop competing full spectrum or spectral flow cytometry platforms with established distribution networks
Regulatory pathway uncertainty for clinical diagnostics applications, which require FDA clearance and CLIA certification, limiting near-term addressable market expansion
Dependence on continued NIH and academic research funding, which faces political and budgetary pressures
growth - The stock attracts investors seeking exposure to life sciences innovation and market share gains in flow cytometry. With negative earnings but 50%+ net income growth (from reduced losses), improving unit economics, and a large addressable market, this appeals to growth-at-reasonable-price investors willing to accept near-term losses for long-term margin expansion. The small $600M market cap and -18.8% one-year return suggest momentum investors have rotated out, leaving fundamental long-term holders.
Trend
-23.0% vs SMA 50 · -23.4% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $203.0M $201.2M–$204.2M | — | $0.15 | — | ±25% | Moderate3 |
FY2025 | $196.7M $196.2M–$197.7M | ▼ -3.1% | -$0.13 | — | ±50% | Moderate3 |
FY2026(current) | $208.8M $208.4M–$209.3M | ▲ +6.2% | -$0.35 | — | ±1% | Moderate3 |
Lilly to provide park and court to the City of Indianapolis as part of its 150th anniversary celebra…
Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CTKB◀ | $3.40 | -8.83% | $440M | — | +51.9% | -3302.3% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.80% | — | 50.3 | +341857.2% | -3973.7% | 1500 |